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Abstract
The development of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2)
serological tests is massive. The external validation of their performance is needed before
use in clinical routine practice. Our study aims at assessing the analytical and clinical
performance of two enzyme‐linked immunosorbent assay tests detecting antibodies di-
rected against the virus nucleocapsid protein: The NovaLisa SARS‐CoV‐2 immunoglobulin
G (IgG), immunoglobulin A (IgA), and immunoglobulin M (IgM) test (NovaTec) allowing a
separate detection of each antibody and the Platelia SARS‐CoV‐2 Total Ab test (Bio‐Rad)
detecting total antibodies (IgM, IgA, and IgG). Two‐hundred and eight coronavirus disease
2019 samples from 48 quantitative reverse transcription‐polymerase chain reaction (RT‐
qPCR) confirmed patients were used to perform the sensitivity analysis. Non‐SARS‐CoV‐2
sera (n = 79) with a potential cross‐reaction to SARS‐CoV‐2 immunoassays were included
in the specificity analysis. In addition, using receiver operator characteristic curves,
adapted cut‐off for improvement of the performances were proposed. The kinetics of
these antibodies was also assessed over 8 weeks. Two weeks after the RT‐qPCR positive
detection, the NovaLisa test shows a sensitivity and specificity of 94.9% (95% confidence
interval [CI]: 83.1%‐98.6%) and 96.2% (95% CI: 89.4%‐98.7%) for IgG, of 89.7% (95% CI:
76.4%‐95.9%) and 98.7% (95% CI: 93.2%‐98.8%) for IgA, and of 48.7% (95% CI: 33.9%‐
63.8%) and 98.7% (95% CI: 93.2%‐99.8%) for IgM. With the Platelia system, the speci-
ficity and sensitivity were 97.4% (95% CI: 92.1%‐99.7%) and 94.9% (95% CI: 87.7%‐
98.0%) for total antibodies using the adapted cut‐offs. The NovaLisa and the Platelia tests
have satisfactory analytical performances. The clinical performances are excellent for IgG,
IgA, and total antibodies especially if the cut‐off is optimized.
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1 | INTRODUCTION
End of 2019, a novel respiratory disease emerged in the city of Wuhan,
Hubei Province of the People's Republic of China. On 7 January 2020,
Chinese authorities determined that these severe cases of pneumonia
were caused by a new coronavirus, temporarily named “2019‐nCoV.”1
This virus, genetically related to the coronavirus responsible for the
2003 severe acute respiratory syndrome (SARS) outbreak, was re-
named SARS coronavirus 2 (“SARS‐CoV‐2”) by the International
Committee on Taxonomy of Viruses on 11 February 2020.2
Since then an unprecedented health, economic and human crisis
has quickly struck the world. By mid‐March 2020, the World Health
Organization European Region had become the epicenter of the
epidemic, reporting more than 40% of confirmed cases worldwide. As
of 28 April 2020, the region was contributing 63% of the global
mortality due to the virus.3 On 8 June, the John Hopkins' University
assessment showed that the virus has spread to 188 countries and
territories, the number of confirmed cases exceeds 6 913 608 million
and the number of deaths worldwide stands at 400 121 deaths.4
In this context of continuous progression of knowledge of cor-
onavirus disease 2019 (COVID‐19) and its evolution, several SARS‐
CoV‐2 immunoassays have been developed. To date, more than 224
different CE marked tests have been identified, including 72 manual or
automated immunoassays.5 Various techniques are available, enzyme‐
linked immunosorbent assay (ELISA), chemiluminescence enzyme im-
munoassays, fluorescence immunoassays, lateral flow immunoassays
to detect immunoglobulin G (IgG), immunoglobulin A (IgA), im-
munoglobulin M (IgM) (separately or in combination) as well as dif-
ferent antibody targets (Spike [S], RBD and/or, nucleocapsid proteins).
It is essential for laboratories to independently validate these
methods before broad introduction into routine clinical practice. In this
context, more and more independent validations of serological tests are
published by analyzing the same sample of sera against different
techniques but also very often with different antibody targets.6‐12
The main objective of our study is to assess and compare the
analytical and clinical performance of two ELISA tests detecting anti-
bodies directed against the nucleocapsid protein of the virus: The No-
vaLisa SARS‐CoV‐2 (COVID‐19) IgG, IgA, and IgM test (NovaTec)
allowing a separate detection of each antibody and the Platelia SARS‐
CoV‐2 Total Ab test (Bio‐Rad) detecting total antibodies (IgM, IgA,
and IgG).
The secondary objectives are to describe the kinetics of these
antibodies over a period of 8 weeks and to clarify the clinical interest
of the independent detection of IgG, IgA, and IgM.
2 | MATERIALS AND METHODS
2.1 | Study design
This retrospective study was conducted from 8 May to 9 June 2020 at
the clinical biology laboratory of the Iris Hospitals South (HIS‐IZZ,
Brussels, Belgium). All the sera (n = 287) originate from blood samples
taken during previous clinical requests for diagnostic purposes and were
stored in the laboratory serum biobank at −20°C. Among these
287 samples, 79 samples were included in the specificity analysis and
were collected before the COVID‐19 outbreak. The remaining 208
samples were included in the sensitivity analysis and were collected from
patients hospitalized for COVID‐19 disease. This study has been ap-
proved by the ethical committee of the HIS‐IZZ (ethical agreement
number: CEHIS/2020‐13).
2.2 | Population
Blood samples positive for COVID‐19 were collected from sympto-
matic patients who came to the emergency room. Table 1 reports on
the number and characteristics of subjects included in the study for
gender, age, extend of disease based on computed tomography scan
criteria, length of hospital stay, place of hospitalization and outcome.
Patients were considered positive according to the results
of the quantitative reverse transcription‐polymerase chain reaction
(RT‐qPCR). The delay between the first onset of symptoms and the
RT‐qPCR is variable and has been estimated at 4 days (±1 day) in our
cohort of 48 patients.
2.3 | Sample collection
Blood samples were collected in serum collection tubes (BD Vacu-
tainer SST II advance, BD, Plymouth, UK) according to procedure
previously described.12
2.4 | ELISA assays
The semi‐quantitative analysis of IgG, IgA, and IgM anti‐SARS‐CoV‐2
nucleocapsid antibodies was carried out by the NovaLisa SARS‐CoV‐2
(COVID‐19) IgG, IgA, and IgM test (NovaTec Immundiagnostica
GmbH, Dietzenbach, Germany) while the semi‐quantitative detection
of total anti‐SARS‐CoV‐2 nucleocapsid antibodies (IgM/IgA/IgG) was
TABLE 1 Demographic characteristics of patients included in the
study
Demography
Age (median [min‐max; 95% CI]) N = 48 (72.0 [21.5‐92.4; 4.4])
Males N = 28
Females N = 20
Length of hospital stay [median
(min‐max; 95% CI)]
N = 39a (21.0 [1.0‐69.0; 4.8])
Delay between symptoms and PCR
[median (min‐max; 95% CI)]
N = 36 (4.0 [0.0‐35.0; 2.1])
Intubated in ICU N = 11
Not intubated in ICU N = 3
Hospitalized (non ICU) N = 30
Not hospitalized N = 4
Survivors N = 42
Non survivors N = 6
Extend of disease (CT scan criteria)
Minimal N = 1
Moderate N = 5
Extended N = 8
Severe N = 12
Critical N = 2
Not categorized N = 11
Negative N = 8
No CT scan N = 1
Abbreviations: CI, confidence interval; CT, computed tomography;
ICU, intensive care unit; PCR, polymerase chain reaction.
a1 patient referred to another hospital; 4 stays in progress.
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carried out by the Platelia SARS‐CoV‐2 Total Ab method (Bio‐Rad,
Marnes‐la‐Coquette, France). Both methods have been implemented
on the ETI‐Max 3000 controller (DiaSorin) after specific programming
according to the manufacturer's instructions. For each ELISA plate, a
ratio between the extinction of the serum samples and the calibrator
was calculated. The interpretation criteria provided by the manu-
facturers are provided in Table 2.
2.5 | Evaluation and comparison of the clinical
performances
2.5.1 | Assessment of the clinical sensitivity
The clinical sensitivity was assessed at several time points since the
confirmation of the diagnostic by RT‐qPCR (n = 208). Thirty‐nine, 35,
39, 34, 22, 17, 14, 6, and 2 sera from 48 positive patients with
COVID‐19, collected respectively at 0 ± 2, 7 ± 2, 14 ± 2, 21 ± 2,
28 ± 2, 35 ± 2, 42 ± 2, 49 ± 2, and 56 ± 2 days since the date of re-
spiratory sampling (t0), were analyzed to detect the appearance of
the antibodies.
2.5.2 | Evaluation of the kinetics appearance of
antibodies
Assessment of the kinetics of IgG, IgA, and IgM appearance in
COVID‐19 positive patients have been carried out by reporting the
levels of antibodies every week for 8 weeks (ie, 7, 14, 21, 28, 35, 42,
49, and 56 days) from the time of the RT‐qPCR positive respiratory
sample.
2.5.3 | Assessment of the clinical specificity
Seventy‐nine samples were tested to assess the cross‐reactivity.
Seventy‐three sera from COVID‐19 negative patients but who had
other viral, bacterial, parasitic or autoimmune pathologies that could
be considered as confounding factors were included in the study. Sera
positive for the following viral, bacterial and infection from parasite
origin were included to assess the possible cross‐reactivity: Hepatitis B
surface antigen (n = 7), hepatitis A virus IgM (n = 3), adenovirus (n = 1),
herpes simplex virus IgM and cytomegalovirus (CMV) IgM (n = 1), IgM
CMV (n = 8), IgM parvovirus B19 (n = 5), human immunodefeciency
virus (n = 1), antistreptolysin O (n = 4), anti‐Treponema pallidum anti-
body (n = 1), IgG Borrelia (n = 1), IgM Mycoplasma pneumoniae (n = 10),
and Toxoplasma gondii IgM (n = 16). The cross‐reactivity of the fol-
lowing autoimmune pathologies was also assessed: rheumatoid factor
(n = 1), anti‐thyroid peroxidase antibody (n = 7), search for irregular
agglutinins (n = 4), direct coombs (n = 1). Finally, one serum with a high
level of total IgM (9.01 g/L) (normal range, 0.40‐2.30 g/L), one serum
with high total IgA (4.47 g/L) (normal range, 0.70‐4.00 g/L), and six sera
from COVID‐19 negative healthy subjects, with no history of known
autoimmune pathologies and without any acute infection of viral or
bacterial origin were included in the study. In these six sera, residues
from old viral infections were present: IgG parvovirus B19 (n = 1), viral
capsid antigen and IgG CMV (n = 2), IgG herpes zoster virus and IgG
Rubella (n = 2), and HBV antibody (n = 1). All these samples were
collected in 2019 before the start of the COVID‐19 outbreak and
were stored at −20°C.
2.6 | Evaluation and comparison of the analytical
performances
Evaluation of the performance was performed in accordance with the
Clinical and Laboratory Standards Institute EP 15‐A3 document.13
The acceptance criteria were defined according to the performance
reported by the manufacturer and are summarized in Table 3.
2.6.1 | Trueness
For NovaLisa and Platelia tests, as there were no positive QC with
two different levels indicated by the manufacturer, trueness has been
estimated by comparing the average value obtained on 20 replicates
of two levels of pool patients to target low and high values re-
presentative of our patient cohort.
2.6.2 | Precision
Precision has been evaluated by analyzing the repeatability (ex-
pressed as intra‐run coefficient of variation [CV]) and the reprodu-
cibility (expressed as inter‐run CV) of the method. The two levels of
pool patients were run in triplicate during 5 consecutive days.
TABLE 2 Interpretation criteria of the NovaLisa SARS‐CoV‐2
(COVID‐19) IgG, IgA, and IgM test (NovaTec and of the Platelia
SARS‐CoV‐2 Total Ab method (Bio‐Rad) on the ETI‐Max 3000
controller
Test Result Interpretation
NovaLisa Ratio <9 Negative
Ratio ≥9 and ≤11 Doubtfula
Ratio >11 Positive
Platelia Ratio <0.8 Negative
Ratio ≥0.8 and <1.0 Doubtfulb
Ratio ≥1.0 Positive
Abbreviations: IgA, immunoglobulin A; IgG, immunoglobulin G; IgM,
immunoglobulin M; SARS‐CoV‐2, severe acute respiratory syndrome
coronavirus 2.
aProcedure: Antibodies against the pathogen could not be detected
clearly. It is recommended to repeat the test with a fresh sample in 2 to
4 weeks. If the result is equivocal again the sample is judged as negative.
bShould be retested in duplicate before final interpretation. In case of
repeated equivocal result, another specimen should be collected and
tested few days later.
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2.6.3 | Limit of blank and detection
The negative control for NovaLisa tests provided by the manufacturer
was used as blank sample to determine the limit of blank (LoB) and limit
of detection (LoD). As there were not enough negative control for
Platelia tests, theses parameters were evaluated with the diluent pro-
vided by the manufacturer. The LoB has been determined by running the
blank sample on three separate occasions. The LoD has been determined
by running 30 analyses of the blank sample using the following equation
according the SH GTA 04 document‐revision 1 of the COFRAC.14
TABLE 3 Acceptance criteria for the evaluation of the analytical performances of the NovaLisa SARS‐CoV‐2 (COVID‐19) IgG, IgA, and IgM
test (NovaTec) and of the Platelia SARS‐CoV‐2 Total Ab method (Bio‐Rad)
Validation
step









Trueness Not reported by the
manufacturer
IgG: Low QC level: 15.72 ± 1.97
High QC level: 42.45 ± 5.54
IgA: Low QC level: 16.55 ± 0.93
High QC level: 106.00 ± 7.96
IgM: Low QC level: 18.20 ± 3.21
High QC level: 50.70 ± 5.64
Not reported by the
manufacturer
Total Ab: Low QC level:
1.34 ± 0.14
High QC level: 1.83 ± 0.24
Precision Repeatability (CV):
IgG: 4.06%‐8.71%







































Not reported by the
manufacturer
Total Ab: 0.25





Not reported by the
manufacturer
Total Ab:0.8%
Specificity Cut‐off of the
manufacturer (>11):
IgG: 99.2%
IgA: Not reported by the
manufacturer
IgM:100%
















Sensitivity Cut‐off of the
manufacturer after
≥12 d post symptoms:
IgG: 100%
IgA: Not reported by the
manufacturer
IgM: 57.1%
Cut‐off of the manufacturer after ≥










between 11 and 20
d post symptoms:
Total Ab: 97%
Cut‐off of the manufacturer




Abbreviations: Ab, antibody; COVID‐19, coronavirus disease 2019; CV, coefficient of variation; IgA, immunoglobulin A; IgG, immunoglobulin G; IgM,
immunoglobulin M; PCR, polymerase chain reaction; SARS‐CoV‐2, severe acute respiratory syndrome coronavirus 2.
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= +
*
Limit of detection mean of the 30 measurements 3
standard deviation
2.6.4 | Evaluation of the carry‐over
A sample with a high level of antibodies was run in triplicate (A1, A2,
and A3) followed by a negative sample also run in triplicate (B1, B2,
and B3). The ratio is calculated using the following equation:
(B1 − B3/A3− B3) × 100. Carry‐over below 1% is considered sa-
tisfactory and is not linked with significant interference.
2.7 | Statistical analyses
Statistical analyses were carried out using MedCalc version 10.4.0.0
(MedCalc Software, Ostend, Belgium). Descriptive statistics were
used to analyze the data. Sensitivity was defined as the proportion of
correctly identified COVID‐19 positive patients who were initially
positive by RT‐qPCR SARS‐CoV‐2 determination in respiratory
samples. Specificity was defined as the proportion of naïve partici-
pants who classified as positive as analyzed by one of the two
methods tested in this study. The adapted cut‐off of the NovaLisa
SARS‐CoV‐2 (COVID‐19) IgG, IgA, and IgM test (NovaTec) and the
Platelia SARS‐CoV‐2 Total Ab method (Bio‐Rad) was determined
using receiver operator characteristic (ROC) curves at 14 ± 2 days
post RT‐qPCR. A Comparative ROC curves for the combined IgG, IgA,
IgM (NovaTec) and total antibodies (Bio‐Rad) was performed. The
highest value of one of the ratios (corresponding either to that of IgG,
IgA, or IgM) was selected for the combined evaluation of the overall
sensitivity of these three antibodies (NovaTec).
3 | RESULTS
3.1 | Evaluation and comparison of the clinical
performances
For the 208 clinical samples, the ranges of calculated index values are
as follow: IgG: (0.62‐44.34); IgA: (0.38‐113.99); IgM: (0.07‐43.90);
total antibodies: (0.05‐3.84).
3.1.1 | Assessment of clinical sensitivity
The sensitivity of the NovaLisa test was 89.7% (95% CI: 76.4%‐
95.9%) for IgG, 84.6% (95% CI: 70.3%‐92.8%) for IgA and 30.8% (95%
CI: 18.6%‐46.4%) for IgM according to manufacturer's cut‐offs in
samples collected 2 weeks after RT‐qPCR positive detection. Best
performances are observed 3 weeks after the RT‐qPCR with values
of 91.2% (95% CI: 77.0%‐97.0%) for IgG and IgA and 38.2% (95% CI:
23.9%‐55.0%) for IgM. For the Platelia Total Ab test, the sensitivity
94.7% (95% CI: 83.1%‐98.6%) according to manufacturer's cut‐offs in
samples collected 2 weeks after RT‐qPCR positive detection. Results
were summarized in Figure 1. Among the 118 samples evaluated
(39 results expected positive and 79 expected negative) 2 weeks
after the RT‐qPCR positive detection, and according to manu-
facturer's cut‐off, the NovaLisa SARS‐CoV‐2 IgG, IgA, and IgM kit
respectively identified 35, 33, 12 true positive and 78, 78, 79 true
negative. Respectively, 4, 6, and 27 samples were classified as false
negative and 1, 1, 0 as false positive with the IgG, IgA, and IgM kit.
On the same cohort, the Platelia SARS‐CoV‐2 Total Ab method
identified 36 true positive and 77 true negative. Two samples were
false positive, and two samples were false negative.
The cut‐offs provided by the ROC curve analyses (ie, ≥7.0 and
≥0.8 for the NovaLisa kit and the Platelia system, respectively)
improve the sensitivity up to 94.9% (95% CI: 83.1%‐98.6%) for IgG,
89.7% (95% CI: 76.4%‐95.9%) for IgA, 48.7% (95% CI: 33.9%‐
63.8%) for IgM and 97.4% (95% CI: 92.1%‐99.7%) for total anti-
bodies. Among the 118 samples tested, the use of these adapted
cut‐offs permits the correct reclassification respectively of the 2,
2, and 7 false negative with the NovaLisa IgG, IgA, and IgM kit to
the detriment of only one false positive case for IgG. Specificity
was not changed for IgA and IgM. For the Platelia test, the use of
the adapted cut‐offs permitted the correct reclassification of the
one false negative to the detriment of two positive case. The
sensitivity and specificity were 94.9% (95% CI: 83.1%‐98.6%) and
96.2% (95% CI: 89.4%‐98.7%) for IgG, and 89.7% (95% CI: 76.4%‐
95.9%) and 98.7% (95% CI: 93.2%‐98.8%) for IgA, and 48.7% (95%
CI: 33.9%‐63.8%) and 98.7% (95% CI: 93.2%‐99.8%) for IgM, and
97.4% (95% CI: 92.1%‐99.7%) and 94.9% (95% CI: 87.7%‐98.0%)
for total antibodies (Table 3) and the kappa index were 0.90 (IgG),
0.90 (IgA), 0.54 (IgM), and 0.87 (IgG, IgA, IgM) for the NovaLisa
and 0.90 (total antibodies) for the Platelia system, respectively
using the adapted cut‐offs.
3.1.2 | Assessment of clinical specificity
From the results obtained above, interference with certain anti-
bodies or antigens produced following viral, bacterial or parasitic
infections or following autoimmune pathologies reveals to be re-
latively low with a specificity of 98.7% (95% CI: 93.2%‐99.8%) for
IgG, 98.7% (95% CI: 93.2%‐99.8%) for IgA, 100% (95% CI: 95.4%‐
100%) for IgM with the NovaLisa tests and 97.5% (95% CI: 91.2%‐
99.3%) for total antibodies with the Platelia system, respectively
using the cut‐offs provided by the manufacturers. Using the
adapted cut‐offs, the specificity was 96.2% (95% CI: 89.4%‐98.7%)
for IgG and 98.7%(95% CI: 93.2%‐98.8%) for IgA, and 98.7% (95%
CI: 93.2%‐99.8%) for IgM and 94.9% (95% CI: 87.7%‐98.0%) for
total antibodies.
The comparative ROC curves for the combination of IgG, IgA,
IgM (NovaTec) and total antibodies (Bio‐Rad) (Figure 3) showed
an area under curve (AUC) at 0.939 for IgG, IgA, IgM (NovaTec)
versus an AUC at 0.933 for total antibodies (Bio‐Rad). No
statistically significant difference was observed between the two
tests (P = 0.749).
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3.1.3 | Evaluation of the kinetics appearance of
antibodies
A peak in antibody production is observed for IgA, IgG, and IgM
3 weeks after PCR.
The values reached for IgA are significantly higher than those for
IgG. Then the IgA values gradually decrease and are no longer de-
tectable at week 8. IgM follow the same decreasing kinetics also from
the third week with an earlier total disappearance of antibodies from
the fourth week. Conversely, IgG reaches a plateau at the third week
and the antibodies maintain this level until the eighth week
(Figure 2). The appearance rate of total antibodies is much faster
than each antibody measured separately and is observed from the
first week post PCR.






F IGURE 1 Evolution of the clinical sensitivity over 8 weeks
according to the manufacturer's cut‐off and the adapted cut‐off for
the NovaLisa SARS‐CoV‐2 (COVID‐19) IgG (A), IgA (B), and IgM (C)
tests and (D) for the Platelia SARS‐CoV‐2 Total Ab method (Bio‐Rad).
IgA, immunoglobulin A; IgG, immunoglobulin G; IgM, immunoglobulin
M; SARS‐CoV‐2, severe acute respiratory syndrome coronavirus 2
(a)
(b)
F IGURE 2 A, Anti‐SARS‐CoV‐2 IgG, IgA, IgM and (B) total
antibody kinetics at different weeks after the RT‐qPCR positive
detection in 48 patients on a total of 208 samples. IgA,
immunoglobulin A; IgG, immunoglobulin G; IgM, immunoglobulin M;
SARS‐CoV‐2, severe acute respiratory syndrome coronavirus 2; RT‐
qPCR, quantitative reverse transcription‐polymerase chain reaction
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3.2 | Evaluation and comparison of the analytical
performances
Table 3 summarizes the analytical performances of the NovaLisa
SARS‐CoV‐2 (COVID‐19) IgG, IgA, and IgM test and the Platelia
SARS‐CoV‐2 Total Ab method. As internal QC were not provided by
the manufacturer, we only report the mean and the standard de-
viation of the two levels of patients' pool for each method, as in-
structed by the manufacturer. The precision shows appropriate
repeatability and reproducibility and are in line with the CVs pro-
vided by the manufacturer. The intra‐ and inter‐run CVs were close
to the range reported by the manufacturer for the two levels of QC.
The most extreme CV value observed was 14.06% for the low QC
reproducibility of IgM. The LoB and detection are below the adapted
cut‐offs with the two tests and the carry‐over is negligible.
4 | DISCUSSION
The interest of serological tests is well recognized today by many na-
tional regulatory authorities in combination with RT‐PCR (which re-
mains the first‐line test for the diagnosis of the acute phase of COVID‐
19) for serosurvelliance or seroepidemiology to identify people being or
having been in contact with the virus. Their external validation of their
performance is however needed before use in clinical routine practice
and some improvement of their performance might be recommended.
This study is the first to describe and compare the analytical and clinical
performances of the NovaLisa SARS‐CoV‐2 (COVID‐19) IgG, IgM, and
IgA kit from NovaLisa and Platelia SARS‐CoV‐2 Total Ab Assay from
Bio‐Rad. We found that the sensitivity increased with time from the first
day until the second week post PCR.
For the two techniques, adaptation of the cut‐offs permits to
achieve a sensitivity of 91.2% for total antibodies for samples col-
lected 1 week after PCR until 97.4% in the second week. In these
samples, the analyses of different immunoglobulins reveal
sensitivities of 94.9% for IgG, 89.7% for IgA, and 48.7% for IgM. In
lights of these results and the data provided by the manufacturer,
assessment of IgM remained limited to be used in clinical practice, as
already reported for other kits assessing IgM suggesting that tech-
nical improvements should be investigated with the firm.
Using the cut‐off provided by the manufacturer, only two false
positives were observed with NovaLisa. These false positives samples
resulted probably from a cross‐reaction with the IgG testing and
were observed in a sample positive for IgM CMV. The second false
positive result originates from serum also positive for IgM CMV and
was reported falsely positive for IgA. For the Platelia, two false po-
sitives were observed, one with IgM Mycoplasma pneumoniae and one
with IgM Toxoplasma gondii. However, as it is the case for most va-
lidations currently published, and given the scarcity of these samples,
we were not able to assess the specificity towards other coronavirus
like the strains 229E (alpha), NL63 (alpha), OC43 (beta), HKU1 (beta),
SARS or Middle East respiratory syndrome.
4.1 | Target antigen and antibody isotype comparison
IgG tests perform better compared with IgA or IgM ones and show
better sensitivity when the samples were taken minimum 2 weeks
after the RT‐qPCR positive detection. Moreover, a combined IgG/
IgA/IgM test seems to be a better choice in terms of sensitivity than
measuring either antibody alone.
Insofar as serological tests have no indication in the acute di-
agnosis of COVID‐19, the advantage of detecting each antibody se-
parately seems very limited in clinical practice. At best IgA appears
earlier than IgG and are detectable from the 1st week.
Regarding the antigenic target, It is essential to compare tests
that target the same antibody detection.15 In this study, we com-
pared for the first time the analytical and clinical performance of two
ELISA tests detecting antibodies directed against the nucleocapsid
protein. The clinical significance of these differences remains un-
known. Do they only witness an infection, or will they witness a
protective and lasting immunity over time?
However, there is a general consensus that SARS‐CoV‐2 neu-
tralizing antibody responses are targeting the S protein.16,17 Of note,
in the longer term, and in the event that a vaccine would become
available, measuring antibody responses to the nucleocapsid (N)
antigen would be informative because most vaccine candidates are
targeting the S protein.18 Measuring the antibody response may help
discriminate between vaccinated (responding to S only) and SARS‐
CoV‐2 exposed individuals (responding to both S and N).
4.2 | Kinetics over 8 weeks
To ensure protective and long‐lasting immunity, it should be known
whether the antibodies are protective and persistent over months. The
majority of studies have focused on the clinical performance of ser-
ological tests during the first 3 weeks post‐symptoms or post‐PCR.19‐22
F IGURE 3 Comparative ROC curves for IgG, IgA, IgM (NovaTec)
and total antibodies (Bio‐Rad) n = 287. Ab, antibody; IgA,
immunoglobulin A; IgG, immunoglobulin G; IgM, immunoglobulin M;
ROC, receiver operator characteristic
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This study, by assessing the antibody kinetics over a period of 8 weeks
provide important data on the persistence of antibodies in infected pa-
tients. The delay between the first onset of symptoms and the RT‐qPCR
is not so variable and has been estimated at 4 days (±1 day) in our cohort
of 48 patients. Previous studies have assessed the presence of antibodies
in serum collected from 0 up to 49 days post symptoms or post PCR.23,24
The kinetics observed in this study is in line with litterature25 showing a
gradual appearance of antibodies between the first and second week
post‐symptom. A production peak was then observed appearing at the
third week followed by a decrease in IgM and IgA from week 4 and 8,
respectively (Figure 2). Based on the demographic characteristics of pa-
tients included in the study and described in Table 1, we did not observe
any clear association between the IgG, IgM, IgA or total antibodies results
and disease severity, although this was already reported in some studies.
Finally, the present study has some limitations. First, monitoring
of antibody dynamics was extended to a maximum of 56 days post
PCR, kinetic analysis over several months will be necessary to
confirm the persistence of antibodies. Second, the number of pa-
tients included in week 8 is too low to confirm a total disappearance
of IgA (n = 2). In addition, the adaptation of the cut‐off must con-
sider the population studied. In our study, the cohort studied only
focused on symptomatic patients who came to the emergency room.
Further investigations are needed to verify whether the appropriate
cut‐offs are also applicable to pauci‐symptomatic and asymptomatic
patients.
5 | CONCLUSION
This study is the first to report the external validation of a new
NovaLisa SARS‐CoV‐2 (COVID‐19) IgG, IgA, and IgM test (NovaTec)
and Platelia SARS‐CoV‐2 Total Ab method (Bio‐Rad) directed against
SARS‐CoV‐2 nucleocapsid. The clinical performances are excellent
for IgG, IgA and total antibodies especially if the cut‐off is optimized.
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